Saturday, May 26, 2018

Aptose Approaching The Clinic With 2 Very Interesting Assets

It has been a long road, but Aptose (APTO) is closing in on getting its two lead drugs into clinical trials. The company still has to resolve a manufacturing-related clinical hold for APTO-253 and finish its pre-IND work on CG’806, but Aptose should have both compounds in human testing in 2019 with initial results from at least APTO-253 before the end of 2019.

Aptose remains an exercise in weighing significant market potential against significant risks and a long road to travel before commercialization. Both APTO-253 and CG-806 have produced intriguing, arguably exciting, pre-clinical data suggesting that they could both be real players in hematology, but the entire point of the clinical trial process is to weed out those drugs that look good in pre-clinical testing but cannot deliver the goods in real-world testing. I believe Aptose shares are undervalued, but investors need to understand and appreciate the significant risks involved and the near-certainty of meaningful future dilution.

Click here for more:
Aptose Approaching The Clinic With 2 Very Interesting Assets

No comments: